LT3601296T - 2-okso-tiazolo derivatai kaip a2a inhibitoriai ir junginiai, skirti naudoti gydant vėžį - Google Patents
2-okso-tiazolo derivatai kaip a2a inhibitoriai ir junginiai, skirti naudoti gydant vėžįInfo
- Publication number
- LT3601296T LT3601296T LTEPPCT/EP2018/058301T LT18058301T LT3601296T LT 3601296 T LT3601296 T LT 3601296T LT 18058301 T LT18058301 T LT 18058301T LT 3601296 T LT3601296 T LT 3601296T
- Authority
- LT
- Lithuania
- Prior art keywords
- cancers
- oxo
- inhibitors
- compounds
- treatment
- Prior art date
Links
- CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical class OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D497/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17163781 | 2017-03-30 | ||
| US201762565281P | 2017-09-29 | 2017-09-29 | |
| EP17194084 | 2017-09-29 | ||
| ARP180100778A AR111200A1 (es) | 2017-03-30 | 2018-03-28 | Derivados de tiocarbamato como inhibidores de a2a y métodos para usar en el tratamiento de cánceres |
| PCT/EP2018/058301 WO2018178338A1 (en) | 2017-03-30 | 2018-03-30 | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3601296T true LT3601296T (lt) | 2022-09-26 |
Family
ID=61911575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2018/058301T LT3601296T (lt) | 2017-03-30 | 2018-03-30 | 2-okso-tiazolo derivatai kaip a2a inhibitoriai ir junginiai, skirti naudoti gydant vėžį |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10995101B2 (lt) |
| EP (2) | EP4112623A1 (lt) |
| JP (2) | JP7197558B2 (lt) |
| KR (2) | KR20240027885A (lt) |
| CN (3) | CN115991679A (lt) |
| AU (1) | AU2018246355B2 (lt) |
| BR (1) | BR112019020421A8 (lt) |
| CA (1) | CA3058260A1 (lt) |
| DK (1) | DK3601296T3 (lt) |
| ES (1) | ES2926158T3 (lt) |
| HR (1) | HRP20221039T1 (lt) |
| HU (1) | HUE059990T2 (lt) |
| IL (2) | IL300149A (lt) |
| LT (1) | LT3601296T (lt) |
| MX (2) | MX2019011743A (lt) |
| PL (1) | PL3601296T3 (lt) |
| RS (1) | RS63557B1 (lt) |
| SI (1) | SI3601296T1 (lt) |
| TW (1) | TWI836960B (lt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3654978A4 (en) | 2017-07-18 | 2021-03-31 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS ADENOSIN ANTAGONISTS |
| CN111093666A (zh) | 2017-07-18 | 2020-05-01 | 诺维逊生物股份有限公司 | 1,8-萘啶酮化合物及其用途 |
| WO2020053263A1 (en) * | 2018-09-11 | 2020-03-19 | Iteos Therapeutics S.A. | Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| US11427594B2 (en) | 2018-09-27 | 2022-08-30 | iTeos Belgium SA | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers |
| US11306071B2 (en) | 2019-01-18 | 2022-04-19 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| AU2020207951A1 (en) | 2019-01-18 | 2021-08-26 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| CN114539265B (zh) * | 2022-03-02 | 2023-07-21 | 中山大学 | 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| US6921825B2 (en) | 1998-09-16 | 2005-07-26 | King Pharmaceuticuals Research & Development, Inc. | Adenosine A3 receptor modulators |
| JP4574112B2 (ja) * | 2000-05-26 | 2010-11-04 | シェーリング コーポレイション | アデノシンａ２ａレセプターアンタゴニスト |
| WO2004092171A2 (en) * | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists |
| MXPA06012231A (es) * | 2004-04-21 | 2006-12-15 | Schering Corp | Antagonistas del receptor a2a de la adenosina con estructura de pirazolo-[4-3-e ]-1,2,4-triazolo-[1,5-c]-pirimidina. |
| WO2007140181A2 (en) | 2006-05-26 | 2007-12-06 | King Pharmaceuticals Research And Development, Inc. | Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist |
| US7723343B2 (en) | 2007-03-30 | 2010-05-25 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2A receptor antagonists |
| AU2008276455A1 (en) | 2007-07-17 | 2009-01-22 | Zalicus Inc. | Combinations for the treatment of B-cell proliferative disorders |
| US20110237599A1 (en) | 2010-03-10 | 2011-09-29 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| WO2012038980A2 (en) | 2010-09-24 | 2012-03-29 | Advinus Therapeutics Limited | Fused tricyclic compounds as adenosine receptor antagonist |
| WO2012055015A1 (en) | 2010-10-26 | 2012-05-03 | Alberta Health Services | Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer |
| WO2012135084A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| TWI812494B (zh) | 2017-01-20 | 2023-08-11 | 美商阿克思生物科學有限公司 | 用於治療癌症相關病症之唑嘧啶 |
| TWI801372B (zh) * | 2017-03-30 | 2023-05-11 | 比利時商艾特歐斯比利時有限公司 | 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法 |
| SG11202005874TA (en) | 2017-12-19 | 2020-07-29 | Impetis Biosciences Ltd | Pharmaceutical composition for the treatment of cancer |
| WO2020053263A1 (en) | 2018-09-11 | 2020-03-19 | Iteos Therapeutics S.A. | Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| WO2020065036A1 (en) | 2018-09-27 | 2020-04-02 | Iteos Therapeutics S.A. | Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist |
| US11427594B2 (en) | 2018-09-27 | 2022-08-30 | iTeos Belgium SA | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers |
-
2018
- 2018-03-30 LT LTEPPCT/EP2018/058301T patent/LT3601296T/lt unknown
- 2018-03-30 TW TW112113401A patent/TWI836960B/zh active
- 2018-03-30 ES ES18716193T patent/ES2926158T3/es active Active
- 2018-03-30 HU HUE18716193A patent/HUE059990T2/hu unknown
- 2018-03-30 IL IL300149A patent/IL300149A/en unknown
- 2018-03-30 JP JP2020503355A patent/JP7197558B2/ja active Active
- 2018-03-30 CN CN202211658370.5A patent/CN115991679A/zh active Pending
- 2018-03-30 KR KR1020247005971A patent/KR20240027885A/ko not_active Application Discontinuation
- 2018-03-30 CN CN202211706953.0A patent/CN115873022A/zh active Pending
- 2018-03-30 AU AU2018246355A patent/AU2018246355B2/en active Active
- 2018-03-30 BR BR112019020421A patent/BR112019020421A8/pt active Search and Examination
- 2018-03-30 EP EP22165965.9A patent/EP4112623A1/en active Pending
- 2018-03-30 SI SI201830747T patent/SI3601296T1/sl unknown
- 2018-03-30 HR HRP20221039TT patent/HRP20221039T1/hr unknown
- 2018-03-30 KR KR1020197031322A patent/KR102640927B1/ko active IP Right Grant
- 2018-03-30 DK DK18716193.0T patent/DK3601296T3/da active
- 2018-03-30 CA CA3058260A patent/CA3058260A1/en active Pending
- 2018-03-30 RS RS20220794A patent/RS63557B1/sr unknown
- 2018-03-30 CN CN201880034926.9A patent/CN110678472B/zh active Active
- 2018-03-30 EP EP18716193.0A patent/EP3601296B1/en active Active
- 2018-03-30 PL PL18716193.0T patent/PL3601296T3/pl unknown
- 2018-03-30 MX MX2019011743A patent/MX2019011743A/es unknown
-
2019
- 2019-03-14 US US16/354,022 patent/US10995101B2/en active Active
- 2019-09-26 IL IL269710A patent/IL269710B2/en unknown
- 2019-09-30 MX MX2022005298A patent/MX2022005298A/es unknown
-
2020
- 2020-08-14 US US16/993,897 patent/US20210198281A1/en not_active Abandoned
-
2022
- 2022-09-21 US US17/949,595 patent/US20230159564A1/en active Pending
- 2022-12-15 JP JP2022199962A patent/JP2023027282A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1249524A1 (zh) | 用於治療血載癌症的免疫檢查點抑制劑 | |
| IL272948B1 (en) | enpp1 inhibitors and their use for cancer treatment | |
| IL269710A (en) | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in cancer therapy | |
| HK1256283A1 (zh) | 治療癌症有用的二氫咪唑並吡嗪酮衍生物 | |
| ZA201807810B (en) | Adenosine derivatives for use in the treatment of cancer | |
| IL258979B (en) | The use of pyrimidine and pyridine history in the treatment of cancer | |
| IL266198A (en) | Liposomal formulation for use in cancer treatment | |
| IL247586A0 (en) | Use of Aribolin and mtor inhibitors as a combined treatment for cancer | |
| IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
| HK1250161B (zh) | 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途 | |
| IL253933A0 (en) | History of pyrimidine use in the treatment of cancer | |
| EP3440052C0 (en) | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| PT3601296T (pt) | Derivados de 2-oxo-tiazóis como inibidores de a2a e compostos para uso no tratamento de cancros |